Oethmaan Biosims Pty Limited Pharmaceutical Import Profile — South Africa (DGFT 2022–2026)

Name: Oethmaan Biosims Pty Limited Pharmaceutical Import Records from India — 2 Products, $641.5K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Oethmaan Biosims Pty Limited — Pharmaceutical Importer Profile (2026) | 2 Products, $641.5K Trade | TransData Nexus

Oethmaan Biosims Pty Limited

Pharmaceutical Importer · South Africa · Advanced Antibiotics Focus · $641.5K Total Trade · DGFT Verified

Oethmaan Biosims Pty Limited is a pharmaceutical importer based in South Africa with a total trade value of $641.5K across 2 products in 2 therapeutic categories. Based on 22 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Oethmaan Biosims Pty Limited sources from 6 verified Indian suppliers, with Milan Laboratories I Private Limited accounting for 35.9% of imports.

Oethmaan Biosims Pty Limited — Import Portfolio & Supplier Network

Oethmaan Biosims Pty Limited import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Oethmaan Biosims Pty Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Milan Laboratories I Private Limited	$841.2K	36	35.9%
Adcock Ingram Limited	$830.1K	59	35.4%
Zeiss Pharma Limited	$464.0K	21	19.8%

What Formulations Does Oethmaan Biosims Pty Limited Import?

Formulation	Value	Ships
Donapan 500MG TAB paracetamol 500MG TAB	$195.3K	8
Donapan 500MG tablets paracetamol 500MG	$148.6K	5
Carvedilol tablets 12.5 MG Pack: 2x14s	$106.2K	3
Pharma.goods/harmless med:ultramox 500169110pacx1x15=2536650capsamoxycillin trihydrate equivalent to amoxycillin 500MG	$100.0K	2
Pharma goods/harmless	$80.9K	4
Seftry 1.0 g INJ 1x10s batch no. iajl4006a, iajl4007a, iajl4008a, iajl4009a, iajl4010a mfg. dt jan,2024 exp. dt dec	$79.3K	3
Donapan 500MG TAB (paracetamol 500MG tablets)	$51.2K	3
Pharma. goods/harmless medicine:ultramox500159860pacx1x15=2397900caps amoxycillin trihydrate equivalent to	$50.0K	1
Seftry 1.0 g INJ 1x10s b/n. iajl3021a. iajl3022a iajl3023a to iajl3025a manufacturing .dt. sep23oct23 exp.dt.	$50.0K	1
Partid-200	$50.0K	1
Lipidex 10MG	$50.0K	1
Lipidex 10MG Each tablet	$50.0K	1
Donapan 500MG tabs paracetamol 500MG	$48.7K	3
Pharma.goods/harmless med:fluoxetine 20oethmaan 173325pacx2x14=4853100 CAPS cont as per	$48.0K	1
Glibenclamide 5 oethmaan tablets	$46.3K	1

Oethmaan Biosims Pty Limited imports 81 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Flucloxacillin	Advanced Antibiotics	$457.8K	10	1.2%	10
2	Glibenclamide	Advanced Diabetes Medications	$183.7K	12	0.3%	6

Oethmaan Biosims Pty Limited imports 2 pharmaceutical products across 2 categories into South Africa totaling $641.5K.

Oethmaan Biosims Pty Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Oethmaan Biosims (Pty) Ltd. is a fully black-owned pharmaceutical company based in Johannesburg, South Africa. Established in October 2016, it emerged from Medreich SA (Pty) Ltd., a company founded in 2003 with a 74.9% foreign ownership and 25.1% local Black South African ownership. Medreich SA primarily focused on pharmaceutical contract manufacturing from its Indian factories, serving clients such as Adcock Ingram, Sandoz, and private label nutraceuticals for Clicks and Dis-Chem. (oethmaan.co.za)

The company is dedicated to providing affordable and accessible medicines to the broader South African public, covering the entire value chain from manufacturing to distribution. It owns its own intellectual property in the form of medicine dossiers, enabling it to make a significant impact on the provision of affordable medicine. Oethmaan Biosims is particularly focused on biosimilar medicines, addressing the increasing costs of treating chronic diseases like cancer in emerging economies. (oethmaan.co.za)

2Distribution Network

Oethmaan Biosims operates from its headquarters at 207A Sherwood House, Greenacres Office Park, Corner of Rustenburg and Victory Roads, Victory Park, Johannesburg, Gauteng, 2195. While specific details about its warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic position in Johannesburg suggests a centralized distribution model. This location provides access to major transportation routes, facilitating efficient distribution within South Africa and potentially to neighboring countries.

3Industry Role

Oethmaan Biosims functions as a pharmaceutical wholesaler and distributor within South Africa's pharmaceutical supply chain. By importing finished pharmaceutical formulations from India and distributing them to various sectors, including private and public healthcare providers, the company plays a crucial role in ensuring the availability of affordable medicines. Its focus on biosimilars aligns with the global trend towards cost-effective treatment options for chronic diseases. (oethmaan.co.za)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Oethmaan Biosims Pty Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Oethmaan Biosims imports finished pharmaceutical formulations from six verified Indian suppliers, with the top four accounting for 95.6% of the total import value. MILAN LABORATORIES I PRIVATE LIMITED leads with 36 shipments valued at $841K (35.9%), followed by ADCOCK INGRAM LIMITED with 59 shipments totaling $830K (35.4%), ZEISS PHARMA LIMITED with 21 shipments amounting to $464K (19.8%), and V S INTERNATIONAL PRIVATE LIMITED with 3 shipments valued at $106K (4.5%). This concentration indicates a strategic choice to maintain stable and reliable supplier relationships, potentially reducing procurement complexities and ensuring consistent product quality. However, such dependency also poses risks; any disruptions with these key suppliers could significantly impact Oethmaan Biosims' ability to meet market demand.

2Supply Chain Resilience

The resilience of Oethmaan Biosims' supply chain is closely tied to its reliance on a limited number of Indian suppliers. While this focus may streamline operations, it also exposes the company to potential risks such as supply disruptions or regulatory changes affecting these suppliers. The diversity of formulations imported—81 unique products—suggests a broad product portfolio, which can mitigate some risks by catering to various therapeutic needs. However, the company's supply chain resilience would benefit from diversifying its supplier base and establishing contingency plans to address potential disruptions.

Importing Pharmaceuticals into South Africa — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for South Africa

1Regulatory Authority & Framework

The South African Health Products Regulatory Authority (SAHPRA) is the primary body responsible for regulating health products, including medicines, in South Africa. SAHPRA operates under the Medicines and Related Substances Act, 1965 (Act No. 101 of 1965), as amended, which provides the legal framework for the regulation of medicines, medical devices, and related substances. This legislation outlines the requirements for the registration, importation, exportation, and distribution of medicines within the country. (sahpra.org.za)

2Import Licensing & GMP

To import medicines into South Africa, companies must obtain a license from SAHPRA, which authorizes them to import and distribute medicines. Additionally, the South African Pharmacy Council requires that pharmaceutical manufacturers and wholesalers be licensed and recorded as manufacturing or wholesale pharmacies. Compliance with Good Manufacturing Practices (GMP) is mandatory, and SAHPRA issues guidelines related to GMP to ensure that medicines meet the required quality standards.

3Quality & Labeling

Oethmaan Biosims Pty Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Oethmaan Biosims' focus on importing advanced antibiotics and advanced diabetes medications aligns with the significant public health needs in South Africa. The high import value of flucloxacillin ($458K) and glibenclamide ($184K) indicates substantial market demand for these therapeutic areas. The company's strategy to import these specific products suggests a targeted approach to address prevalent health issues, such as bacterial infections and diabetes, thereby contributing to the overall healthcare landscape in South Africa.

2Sourcing Profile

Oethmaan Biosims' sourcing strategy emphasizes importing finished pharmaceutical formulations from India, focusing on generic drugs. This approach allows the company to offer cost-effective treatment options while maintaining quality standards. The selection of formulations is likely driven by market demand and the company's therapeutic focus areas, ensuring that the imported products meet the specific needs of the South African population.

3Market Positioning

Based on its product mix, Oethmaan Biosims serves multiple segments of the South African pharmaceutical market, including retail pharmacies, hospitals, and government tenders. By providing a diverse range of affordable medicines, the company positions itself as a key player in both the private and public healthcare sectors, contributing to the accessibility and affordability of essential medicines across the country.

Seller's Guide — How to Become a Supplier to Oethmaan Biosims Pty Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the South African market by meeting Oethmaan Biosims' quality standards and regulatory requirements. The company's focus on biosimilars and cost-effective treatments aligns with the global trend towards affordable healthcare solutions. Potential gaps in Oethmaan Biosims' current sourcing include the need for additional suppliers to diversify its supply chain and mitigate risks associated with supplier concentration.

2Requirements & Qualifications

Indian exporters seeking to supply Oethmaan Biosims and the South African market must obtain a license from SAHPRA, ensuring compliance with local regulations. Adherence to Good Manufacturing Practices (GMP) is mandatory, and certifications such as EU GMP, WHO GMP, or PIC/S are recognized. Additionally, compliance with labeling requirements, including language and serialization mandates, is essential to meet regulatory standards. (sahpra.org.za)

3How to Approach

Frequently Asked Questions — Oethmaan Biosims Pty Limited

What products does Oethmaan Biosims Pty Limited import from India?

Oethmaan Biosims Pty Limited imports 2 pharmaceutical products across 2 categories. Top imports: Flucloxacillin ($457.8K), Glibenclamide ($183.7K).

Who supplies pharmaceuticals to Oethmaan Biosims Pty Limited from India?

Oethmaan Biosims Pty Limited sources from 6 verified Indian suppliers. The primary supplier is Milan Laboratories I Private Limited (35.9% of imports, $841.2K).

What is Oethmaan Biosims Pty Limited's total pharmaceutical import value?

Oethmaan Biosims Pty Limited's total pharmaceutical import value from India is $641.5K, based on 22 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Oethmaan Biosims Pty Limited focus on?

Oethmaan Biosims Pty Limited imports across 2 categories. The largest: Advanced Antibiotics (71.4%), Advanced Diabetes Medications (28.6%).

Get Full Oethmaan Biosims Pty Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.